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GGE phenotype in the context of a CAPN3mutation.
2. Clinical cases
Fig. 1 shows the pedigree of the family. We performed genetic anal-
yses on the third generation and one subject of the second generation.1. Introduction
Muscular dystrophies are a heterogeneous group of inherited dis-
eases that cause progressive muscle weakness. The association of epi-
lepsy with some of these diseases has been previously described and
has most commonly been found for Fukuyama-type muscular dystro-
phy due to alterations in cerebral neuronal migration [1]. Among mus-
cular dystrophies, limb-girdle muscular dystrophies (LGMDs)
represent the fourth most common group, with a prevalence of 1.63
per 100,000 individuals [2]. The diseases in this group share a common
phenotype involving progressive weakness of the scapular and pelvic
girdles that starts after 2 years of age and can be accompanied by differ-
ent degrees of elevation in blood creatine kinase (CK) levels and by var-
ious anatomic pathological findings. LGMDs are subdivided into LGMD1
and LGMD2 depending on whether the inheritance is dominant or re-
cessive, respectively. LGMD2A, which is caused by deficiency of the
calpain 3 protein owing to mutations in the CAPN3 gene, is the most
common form of LGMD in Europe and America [2]. Its association
with epilepsy has been described in only two isolated cases [1,3], both
of them on the spectrum of genetic generalised epilepsies (GGEs). The
latter are the most common group of epilepsies with genetic aetiology,
accounting for 15–20% of all epilepsy cases [4]. Nonetheless, none of the
genes usually involved in monogenic epilepsies seem to play a major
role in GGE, probably indicating a polygenic predisposition to GGE and
therefore a complex inheritance pattern [5]. Here, we describe a familyebesque).
. This is an open access article underin which a case of LGMD2A is combined with cases of epilepsy having a
2.1. Subject 1
Subject 1 is a 25-year-old male with a juvenile myoclonic epilepsy
(JME) phenotype. He exhibited normal psychomotor development but
started having epileptic seizures, including generalised tonic–clonic sei-
zures (GTCSs), myoclonic seizures, and sporadic absence seizures, at 16
years of age. He did not presentmuscular symptoms, and CK levelswere
normal. Structural alterations were not present on cerebral magnetic
resonance imaging; on the electroencephalogram (EEG), generalised
spike and wave discharges were observed. The patient received treat-
ment with valproic acid (VPA), which has maintained sporadic fre-
quency of myoclonic seizures. The patient is heterozygous for a
frameshift mutation c.2362_2363delinsTCATCT in exon 22 of the
CAPN3 gene.
2.2. Subject 2
This subject is a 24-year-old man who had normal psychomotor de-
velopment and is presently asymptomatic, with normal CK levels. At
age 10, he experienced two GTCSs; after the second, he started treatment
with VPA, which was continued for 4 years. The treatment was
discontinued before the disappearance of seizures, and there was no sub-
sequent recurrence of the seizures. In this study, alterations were not de-
tected by cerebral computed tomography scans, but generalized interictal
epileptiform discharges were noted on several EEGs. The patient is het-
erozygous for the frameshift mutation c.2362_2363delinsTCATCT in
exon 22 of the CAPN3 gene but has no muscular symptoms.
2.3. Subject 3
Subject 3 is an 18-year-old woman free of bothmuscular symptoms
and epileptic seizures. She does not have the familial mutation in the
CAPN3 gene.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Pedigree of the studied family. Grey colour represents an epilepsy phenotype. Black
colour denotes the LGMD2A phenotype.
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This subject is a 16-year-old male with the LGMD2A phenotype. He
showednormal psychomotor development, but at the age of 9, he began
manifesting clinical weakness of the pelvic girdle, tiptoe walking, slight
lumbar hyperlordosis, difficulty walking on his heels, and a positive
Gower's sign. He had elevated CK levels (6426 UI/L, reference range 0–
171). He has not manifest with seizures thus far. He is homozygous
for the frameshift mutation c.2362_2363delinsTCATCT in exon 22 of
the CAPN3 gene.
2.5. Other members of the family
Subjects 5, 6, and 7 – the father, paternal aunt, and paternal grandfa-
ther of the above-mentioned subjects, respectively –have epilepsy. Sub-
jects 5 and 6 are 53 and 55 years old, respectively; they have a well-
controlled form of GGE with isolated GTCSs, both are seizure-free due
to treatment with VPA. They have not developed muscular symptoms,
and CK levels have been normal or slightly elevated in different mea-
surements in both subjects (between 135–193 and 145–197 UI/L, re-
spectively). Subject 5 is heterozygous for the familial mutation.
Nevertheless, we do not have other clinical or genetic data on subjects
6 and 7.
3. Discussion
LGMD2A, or calpainopathy, is one form of LGMD that until now has
been associated with epilepsy in only two cases [1,3]. The first case was
that of a 12-year-old boy with the LGMD phenotype in whom a partial
calpain deficiency was found by western blotting of muscle protein; at
age 7, the boy developed typical absence seizures with generalized
spike–wave discharges at 3 Hz on the EEG and was treated with
ethosuximide, which provided good seizure control. The boy had no
family history of epilepsy, but two of his sisters showedmuscle involve-
ment [1]. The second case was that of a 14-year-old girl with clinical
signs of girdle muscle weakness and two heterozygous mutations in
the CAPN3 gene (themissense A2288Gmutation and the 100delG dele-
tion in codon 763); at the age of 13, she experienced absence seizures
and showed typical generalized epileptiform discharges on an EEG.
The girl was successfully treated with VPA. In this case, the patient's sis-
ter also presented with epilepsy with absence seizures and GTCSs but
had not experienced muscle involvement and had not undergone ge-
netic analysis [3].
Here, we described several members of a family with a CAPN3muta-
tion that gave rise to the LGMD2A phenotype in a single homozygoussubject and is also associated with epilepsy in several family members,
including three subjects who are heterozygous for the knownmutation.
The epilepsy type of these three subjects can be categorized as GGE: one
subject has a clear JME phenotype, and two subjects have GGEwith iso-
lated GTCSs. The mutation present in this family (frameshift
c.2362_2363delinsTCATCT in exon 22) has been described [6]. It is pos-
sible that the coexistence of the mutations in the CAPN3 gene and epi-
lepsy are coincidental. Nonetheless, there are some data suggestive of
a possible association. On the one hand, the subjects with epilepsy and
amutation in the CAPN3 gene have the phenotype of a specific epileptic
syndrome, GGE, in common. In addition, among the subjects studied by
genetic analysis, the only one who has not developed epilepsy does not
have the heterozygousmutation, with the other three known heterozy-
gous subjects having developed GGE. These two findings, although they
are not direct evidence, point to a possible relation between CAPN3mu-
tations and GGE. On the other hand, given the high prevalence of GGE
[5], another possibility is the casual relation between these two genetic
entities in the same family, with the known mutation causing only the
LGMD phenotype in subject 4.
As mentioned above, GGE has a complex inheritance pattern involv-
ingmultiple genetic factors. In addition, environmental factors probably
also play a role in GGE pathogenesis, and this situation can lead to phe-
notypic variations amongmembers of the same family [5]. This could be
the case for the family studied in the present work where we observed
different GGE phenotypes: from a JME phenotype to the phenotype of
GGE with GTCSs and benign evolution that remains in remission with-
out treatment. In the genetic complexity of GGE, susceptibility variants
at different loci have been documented [5]. Thus far, it has not been
proven that the chromosomal 15q15.1 region – the location of the
CAPN3 gene, which encodes calpain 3 and is responsible for LGMD2A
whenmutated – is related to genetic epilepsy. Calpain 3 is a calcium-de-
pendent protease located mainly in mammalian skeletal muscle; how-
ever, the presence of calpain 3 mRNA has also been detected in other
tissues, including brain tissues, and in cells with a neuronal phenotype
[7,8]. The activation of calpain by the influx of intracellular calcium
through NMDA receptors cleaves the GluR1 domain of AMPA receptors,
resulting in inhibition of excitatory ion currents [9]; this regulatory
function of AMPA receptors may be aberrant in patients withmutations
in CAPN3 and could thus be related to the pathophysiology of epilepsy.
Nevertheless, there is currently no clear evidence regarding the possible
participation of calpain 3 in epilepsy, particularly at the level of the cen-
tral nervous system, and to date, reports linking a deficiency of this pro-
tein to LGMD2Awith epilepsy have been rare. Therefore, future reports
of new cases and an expansion of the body of knowledge about calpain 3
physiology and the genetics of GGE are necessary for further research
into this association.
4. Conclusions
We presented a unique case of a family in which LGMD2A is associ-
atedwith GGE. Despite the possibility of a serendipitous link, we believe
that it is important to report all cases that relate these two conditions to
elucidate their possible association and to test the hypothesis that mu-
tations in CAPN3 are some of the many predisposing factors related to
the complex genetic aetiology of GGE.
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